SARCOPENIA PA am eM ee RNA O IG 890,096 The prevalent population of population of Sarcopenia in 7MM Sarcopenia i in 2017 in 2017 Japan in 2017 (DY Score o- Sarcorenia Report /-— Descriptive overview of Sarcopenia and country specie treatmant algorithms Detailed Sarcopenia epidemiology ‘segmentation along with forecast up to 2030 Current and emerging therapies, drug uptake and assessment cf new therapies for Sarcopenia \— ooetaita review of Sarcopenia markt; historical and forecasted trends up to 2030 aren ray Soe Pee eg The prevalence of Sarcopenia by Gender in the United States in 2017 fp 9,932,700 Males MARKET DRIVERS aby Better insight into disease intervention Increase in research initiatives eau A p7907. 238 Females [Need for » cost effective therapy MARKET BARRIERS. Diagnosis associated shor teomings. EMERGING DRUGS ‘ophytis } @ sown) Sarconeos Bimagrumab ‘AMAZ-02 OTHER PROMISING THERAPIES Rerort Coverace SANOFI > EGENERON tS) REPORT FEATURES 5B rnporsementScnao Major Countries O7 wees noes QB ‘hoa Fave : assess —= . 33 “a ‘tie rey pores O7 : 44 “inns PF 1801, PB1023 RELATED REPORTS 1 1 i 1 |B Sarcopenia- Epidemiology Forecast 2030! ' | Sorcopenia - Pipeline Insights, 2020